{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17(6)"],"submitter":["Jin S"],"pubmed_abstract":["Extracellular vesicles (EVs)-based cell-free therapy, particularly stem cell-derived extracellular vesicles (SC-EVs), offers new insights into treating a series of neurological disorders and becomes a promising candidate for alternative stem cell regenerative therapy. Currently, SC-EVs are considered direct therapeutic agents by themselves and/or dynamic delivery systems as they have a similar regenerative capacity of stem cells to promote neurogenesis and can easily load many functional small molecules to recipient cells in the central nervous system. Meanwhile, as non-living entities, SC-EVs avoid the uncontrollability and manufacturability limitations of live stem cell products <i>in vivo</i> (<i>e.g.</i>, low survival rate, immune response, and tumorigenicity) and <i>in vitro</i> (<i>e.g.</i>, restricted sources, complex preparation processes, poor quality control, low storage, shipping instability, and ethical controversy) by strict quality control system. Moreover, SC-EVs can be engineered or designed to enhance further overall yield, increase bioactivity, improve targeting, and extend their half-life. Here, this review provides an overview on the biological properties of SC-EVs, and the current progress in the strategies of native or bioengineered SC-EVs for nerve injury repairing is presented. Then we further summarize the challenges of recent research and perspectives for successful clinical application to advance SC-EVs from bench to bedside in neurological diseases."],"journal":["Asian journal of pharmaceutical sciences"],"pagination":["779-797"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9800941"],"repository":["biostudies-literature"],"pubmed_title":["Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cells."],"pmcid":["PMC9800941"],"pubmed_authors":["Lv Z","Shen L","Liu J","Jin S","Tan C","Wang J","Kang L","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cells.","description":"Extracellular vesicles (EVs)-based cell-free therapy, particularly stem cell-derived extracellular vesicles (SC-EVs), offers new insights into treating a series of neurological disorders and becomes a promising candidate for alternative stem cell regenerative therapy. Currently, SC-EVs are considered direct therapeutic agents by themselves and/or dynamic delivery systems as they have a similar regenerative capacity of stem cells to promote neurogenesis and can easily load many functional small molecules to recipient cells in the central nervous system. Meanwhile, as non-living entities, SC-EVs avoid the uncontrollability and manufacturability limitations of live stem cell products <i>in vivo</i> (<i>e.g.</i>, low survival rate, immune response, and tumorigenicity) and <i>in vitro</i> (<i>e.g.</i>, restricted sources, complex preparation processes, poor quality control, low storage, shipping instability, and ethical controversy) by strict quality control system. Moreover, SC-EVs can be engineered or designed to enhance further overall yield, increase bioactivity, improve targeting, and extend their half-life. Here, this review provides an overview on the biological properties of SC-EVs, and the current progress in the strategies of native or bioengineered SC-EVs for nerve injury repairing is presented. Then we further summarize the challenges of recent research and perspectives for successful clinical application to advance SC-EVs from bench to bedside in neurological diseases.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-04T08:33:44.726Z","creation":"2025-04-04T08:33:44.726Z"},"accession":"S-EPMC9800941","cross_references":{"pubmed":["36600903"],"doi":["10.1016/j.ajps.2022.10.002"]}}